---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006911"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:08:46.973816+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Q3 net loss $10.0M ($0.08/shr); cash $164M; CEO succession to Bisker-Leib

## Summary
- Net loss for Q3 2023 was $10.0M ($0.08/shr) vs $12.0M ($0.12/shr) in Q3 2022; 9-month net loss $29.1M.
- Cash and marketable securities $164M as of Sep 30, 2023, providing cash runway into 2026.
- CEO succession: President/COO Vered Bisker-Leib to become CEO; current CEO Thomas Schuetz to President of R&D and Vice Chair, effective Jan 9, 2024.
- CTX-009 Ph2/3 COMPANION-002 (BTC) top line data expected H2 2024; initial data from COMPANION-003 (CRC) expected by year-end 2023.
- CTX-8371 IND cleared; Phase 1 trial to start Q4 2023. CTX-471 dose-escalation completed; expansion expected Q1 2024.

## SEC filing metadata
- accession: 0001171843-23-006911
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/0001171843-23-006911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/f8k_110823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006911
- JSON: https://secwatch.observer/filing/0001171843-23-006911.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006911.txt

## Key facts
- Earnings Releases
  Compass Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share, EPS $0.08 per common share.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share
  - EPS: $0.08 per common share
  - Result: reported results
  source text: On November 9, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/0001171843-23-006911-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.